EMERYVILLE, Calif.--(BUSINESS WIRE)-- The panel at the Global Discovery to Development Innovation Summit (www.gddis.com) will focus on leveraging recent innovations in translational tools, biomarkers and genomics to generate more meaningful drug discovery data. The panel will also evaluate methods of creating an “integrated approach” for using new technologies to generate more effective results.
In addition to Dr. Hellerstein the Panel will include:
- Vicki Seyfert-Margolis, Ph.D., Senior Advisor, Science Innovation and Policy Office of the Chief Scientist, Office of the Commissioner, Food and Drug Administration (Panel Chair)
- Prof. Thomas Herget, Senior Director, New Technology Evaluation, Division Chemicals R&D, Merck KGaA
- Duncan McHale, Vice President, Translational Sciences, Discovery Enabling Capabilities & Science, AstraZeneca
- Kalpana M. Merchant, Ph.D., Chief Scientific Officer Translational Science, Research, Laboratories at Eli Lilly Company
- Michael Dorato, Ph.D., D.A.B.T., Vice President, Discovery Services Covance, Discovery & Translational Services
- Dr. Tony Owen, Worldwide Director of Marketing Chromatography & Informatics Software Agilent Technologies
Dr. Hellerstein commented, “This panel discussion will address a question central to contemporary drug development: how do we navigate through the complexity of living systems to a desired clinical outcome?
"The fundamentally unpredictable biologic consequences of molecular-target based interventions in complex living systems, particularly for novel targets, often prevent translating preclinical findings into human biology and clinical outcomes. This unpredictability is the primary explanation for the high attrition rates of modern drug candidates.
"There is a solution: namely, to stop driving blind, and to make development of medicines a measurement science rather than a series of guesses. This requires tools for measuring the processes that are responsible for the initiation, progression, severity and therapeutic reversal of common diseases. These processes can be termed the causal pathways of disease. Metrics need to be predictive and translatable into humans.
"I will discuss KineMed's platform of causal pathway metrics, focusing on recent advances that greatly expand the breadth of measurable processes. Emphasis will be on examples of cost-effective, data-driven drug development by use of these tools.”
About KineMed, Inc.
KineMed, Inc. ("KineMed" or the "Company") is a drug discovery and development company employing its proprietary translational medicine technology (AquaTag™ and KineMarker™) to both identify active drug candidates preclinically and confirm their therapeutic activity and dose response in first-in-man studies. The Company is working to develop drugs both on its own and with pharmaceutical collaborators in therapeutic focus areas where it can demonstrate functional modulation of specific biological pathways that mediate disease.
KineMed's technology expedites the drug development process and provides real-time insight into conditions including metabolic disorders, cancer, fibrotic diseases, inflammation, and neurodegeneration.
For further information about KineMed, please visit: http://www.kinemed.com.
Lila Taylor, 510-655-6525 ext. 141
Director of Business Development
KEYWORDS: United States North America California Florida
INDUSTRY KEYWORDS: Health Biotechnology Pharmaceutical